Aytu BioPharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Aytu BioPharma, Inc. (AYTU) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2019FY 2018
Period EndingDec 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2019Jun 2018
Operating Activities
Net Income-13.56-15.84-17.05-108.78-58.29-27.13-10.19
Depreciation & Amortization5.386.739.3710.159.202.732.59
Stock Based Compensation0.582.375.725.253.570.000.00
Change in Working Capital-5.73-6.73-5.80-10.861.68-0.21-0.72
Change in Accounts Receivable-7.635.20-7.246.531.540.000.00
Change in Inventory0.38-4.82-3.491.302.790.000.00
Change in Accounts Payable0.29-2.083.09-7.68-3.250.000.00
Change in Other Working Capital1.23-5.032.65-1.850.600.000.00
Other Operating Activities11.416.0614.11-1.854.449.84-6.28
Net Cash from Operating Activities-1.94-1.39-5.13-28.82-25.96-13.83-15.94
Investing Activities
Capital Expenditures-3.23-0.330.000.00-2.34-0.06-0.07
Acquisitions0.000.00-0.97-3.18-0.48-0.51-0.01
Sales/Maturities of Investments0.00-0.33-0.12-0.070.040.000.00
Other Investing Activities-2.33-0.33-0.12-0.070.04-0.50-0.40
Net Cash from Investing Activities-2.56-0.33-0.12-3.25-2.78-1.06-0.48
Financing Activities
Debt Repayment6.67-15.72-0.19-20.22-54.950.000.00
Common Stock Issued14.843.4715.5811.6940.1515.1824.74
Other Financing Activities-6.07-2.84-4.27-4.94-6.09-1.48-2.76
Net Cash from Financing Activities15.44-1.268.871.5330.3119.0822.66
Summary
Net Change in Cash10.95-2.983.63-30.541.574.186.23
Cash at Beginning of Period20.0122.9919.3649.9048.337.110.88
Cash at End of Period30.9520.0119.3619.3698.2011.297.11
Free Cash Flow-5.17-1.72-5.13-28.82-28.31-13.89-16.02
Supplemental Disclosures
Interest Paid2.824.043.813.151.250.000.00
Income Taxes Paid1.421.610.000.000.000.000.00